List of works - Nicolas Meyer

(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.

scientific article published on 21 November 2013

A case of merkel leptomeningeal evolution after complete remission upon anti-PD-1 treatment

scientific article published on 11 April 2019

Acute interstitial nephritis related to immune checkpoint inhibitors.

scientific article published on 10 November 2016

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.

scientific article published on 26 August 2015

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

scientific article published on 10 September 2017

Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients

scientific article published on 06 August 2019

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

scientific article published on 01 December 2018

BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.

scientific article

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

scientific article published on 12 February 2018

Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.

scientific article published on 26 August 2014

CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.

scientific article published on 10 November 2012

Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma

scientific article published on 15 August 2018

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy

scientific article published on 05 July 2018

Communicating information to the general practitioner: the example of vemurafenib for metastatic melanoma

scientific article published on 11 November 2015

Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.

scientific article

Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy

scientific article

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

scientific article published on 28 August 2017

Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients

scientific article published on 01 December 2019

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

scientific article published on 02 June 2017

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

scientific article published on 28 April 2016

Does needle biopsy cause an increased risk of extracapsular extension in the diagnosis of metastatic lymph node in melanoma?

scientific article published on 12 February 2018

Double-positive CD4/CD8 mycosis fungoides: a rarely reported immunohistochemical profile.

scientific article published on 20 November 2013

Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy

scientific article published on 01 February 2019

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

scientific article published on 02 December 2018

Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.

scientific article published on 23 December 2017

Enzalutamide induced acute generalized exanthematous pustulosis.

scientific article published on 13 November 2016

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

scientific article published on 27 February 2019

Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation.

scientific article published on June 2014

High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study

scientific article published on 30 September 2014

Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

scientific article

Incidence and risk factors for treatment failure with infliximab in psoriasis.

scientific article published on 7 January 2013

Outbreak of contact sensitization to methylisothiazolinone: an analysis of French data from the REVIDAL-GERDA network

scientific article

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect

scientific article

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.

scientific article published on 23 August 2017

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

scientific article published on 30 April 2019

Staging of primary cutaneous follicle centre B-cell lymphoma: bone marrow biopsy, CD10, BCL2 and t(14;18) are not relevant prognostic factors

scientific article published on 17 April 2019

Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study.

scientific article published on 28 September 2016

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

scientific article published on 22 December 2017

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

scientific article published on 27 November 2018

The TNF Paradox in Cancer Progression and Immunotherapy

scientific article published on 31 July 2019

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.

scientific article

Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab.

scientific article published on 3 June 2016

Vemurafenib significantly decreases glomerular filtration rate.

scientific article

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

scientific article published on 23 October 2017

[An unusual mediastinal mass].

scientific article published on 11 December 2013

[Anti-TNFα antibodies in melanoma immunotherapy]

scientific article published on 01 October 2018

[Dermatologic toxicities of immune checkpoint inhibitors]

scientific article published on 18 April 2018

[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].

scientific article published on 27 June 2016

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]

scientific article published on 13 September 2018

[Treatment of patients with brain metastases from a melanoma]

scientific article published on 21 March 2019

[What's new in oncodermatology in 2015?]

scientific article published on 01 December 2015

List of works by Nicolas Meyer

(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.

A case of merkel leptomeningeal evolution after complete remission upon anti-PD-1 treatment

Acute interstitial nephritis related to immune checkpoint inhibitors.

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.

CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.

Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy

Communicating information to the general practitioner: the example of vemurafenib for metastatic melanoma

Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.

Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

Does needle biopsy cause an increased risk of extracapsular extension in the diagnosis of metastatic lymph node in melanoma?

Double-positive CD4/CD8 mycosis fungoides: a rarely reported immunohistochemical profile.

Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.

Enzalutamide induced acute generalized exanthematous pustulosis.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation.

High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study

Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

Incidence and risk factors for treatment failure with infliximab in psoriasis.

Outbreak of contact sensitization to methylisothiazolinone: an analysis of French data from the REVIDAL-GERDA network

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

Staging of primary cutaneous follicle centre B-cell lymphoma: bone marrow biopsy, CD10, BCL2 and t(14;18) are not relevant prognostic factors

Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

The TNF Paradox in Cancer Progression and Immunotherapy

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.

Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab.

Vemurafenib significantly decreases glomerular filtration rate.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

[An unusual mediastinal mass].

[Anti-TNFα antibodies in melanoma immunotherapy]

[Dermatologic toxicities of immune checkpoint inhibitors]

[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]

[Treatment of patients with brain metastases from a melanoma]

[What's new in oncodermatology in 2015?]